Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Zymeworks Presents New Preclinical Data at the Society for Immunotherapy of Cancer Conference
We are pleased to present preclinical data on our multispecific antibody programs in poster presentations at the 40th annual Society for Immunotherapy of Cancer (SITC) Conference, taking place November 5-9 in National Harbour, MD. Presentation Highlights Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity Abstract Number: 853 […]
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
Zymeworks Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer Annual Meeting
We are excited to announce two poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, MD. Presentation Details Title: Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity Abstract Number: 853 Date: November 7 Category: Immune-Stimulants […]
Zymeworks Presents Preclinical Data on ZW1528 at the European Respiratory Society Annual Congress
We are pleased to present preclinical data for ZW1528, a novel IL-4Rα x IL-33 bispecific molecule designed to address respiratory inflammation, at the at European Respiratory Society (ERS) Congress 2025, taking place September 27 – October 1, 2025, in Amsterdam, Netherlands and virtually. The poster presentation titled “ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, […]
Zymeworks Announces Presentation at the European Respiratory Society (ERS) Congress 2025
Zymeworks is attending and presenting at European Respiratory Society (ERS) Congress 2025, taking place September 27 – October 1, 2025, in Amsterdam, Netherlands and virtually. Presentation details: Abstract Title: ZW1528: A dual-targeting bispecific antibody to broadly suppress airway inflammation by inhibiting IL-4Ra and IL-33 pathways Poster Number: PA4587 Presenter: Blair K. Hardman, Ph.D. Session#391: Biologics […]
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
Zymeworks Announces Participation in Upcoming Investor Conferences
